Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
Janbernd Kirschner, Nina Butoianu, Nathalie Goemans, et al.
European Journal of Paediatric Neurology (2020) Vol. 28, pp. 38-43
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)
Tolu Ogbonmide, Rajni Rathore, Shahid B Rangrej, et al.
Cureus (2023)
Open Access | Times Cited: 61
Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study
Didu Kariyawasam, Arlene D’Silva, Hugo Sampaio, et al.
The Lancet Child & Adolescent Health (2023) Vol. 7, Iss. 3, pp. 159-170
Closed Access | Times Cited: 45
Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry
Laurent Servais, John Day, Darryl C. De Vivo, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 425-442
Open Access | Times Cited: 26
Challenges and opportunities in spinal muscular atrophy therapeutics
Crystal Jing Jing Yeo, Eduardo F. Tizzano, Basil T. Darras
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 205-218
Closed Access | Times Cited: 21
Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance
Melissa C. Keinath, Devin E. Prior, Thomas W. Prior
The Application of Clinical Genetics (2021) Vol. Volume 14, pp. 11-25
Open Access | Times Cited: 102
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
John Day, Jerry R. Mendell, Eugenio Mercuri, et al.
Drug Safety (2021) Vol. 44, Iss. 10, pp. 1109-1119
Open Access | Times Cited: 91
New therapies for spinal muscular atrophy: where we stand and what is next
Laura Antonaci, Maria Carmela Pera, Eugenio Mercuri
European Journal of Pediatrics (2023) Vol. 182, Iss. 7, pp. 2935-2942
Open Access | Times Cited: 27
2024 update: European consensus statement on gene therapy for spinal muscular atrophy
Janbernd Kirschner, G. Bernert, Nina Butoianu, et al.
European Journal of Paediatric Neurology (2024) Vol. 51, pp. 73-78
Open Access | Times Cited: 12
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Virginie Baylot, Thi Khanh Le, David Taïeb, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 10
The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review
Claudia Dosi, Riccardo Masson
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 9
Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre Experience
Johannes Friese, Stephanie Geitmann, Dorothea Holzwarth, et al.
Journal of Neuromuscular Diseases (2021) Vol. 8, Iss. 2, pp. 209-216
Open Access | Times Cited: 56
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy
Elizabeth Kichula, Crystal M. Proud, Michelle A. Farrar, et al.
Muscle & Nerve (2021) Vol. 64, Iss. 4, pp. 413-427
Open Access | Times Cited: 51
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study
Claudia Weiß, Andreas Ziegler, Lena‐Luise Becker, et al.
The Lancet Child & Adolescent Health (2021) Vol. 6, Iss. 1, pp. 17-27
Closed Access | Times Cited: 51
Gene therapy for spinal muscular atrophy: the Qatari experience
Hossamaldein Gaber Ali, Khalid Ibrahim, Mahmoud F. Elsaid, et al.
Gene Therapy (2021) Vol. 28, Iss. 10-11, pp. 676-680
Open Access | Times Cited: 42
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1865-1883
Open Access | Times Cited: 38
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
Hannah A. Blair
CNS Drugs (2022) Vol. 36, Iss. 9, pp. 995-1005
Open Access | Times Cited: 38
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy
Hugh J. McMillan, Crystal M. Proud, Michelle A. Farrar, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 9, pp. 1075-1090
Open Access | Times Cited: 29
Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
Andreas Hahn, René Günther, Albert C. Ludolph, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 29
“We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy
Didu Kariyawasam, Arlene D’Silva, Janine Vetsch, et al.
EClinicalMedicine (2021) Vol. 33, pp. 100742-100742
Open Access | Times Cited: 36
Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
Giovanni Baranello, Ksenija Gorni, Monica Daigl, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 6, pp. 1435-1454
Open Access | Times Cited: 33
Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape
Aleksei S. Ponomarev, Daria S. Chulpanova, Lina M. Yanygina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13743-13743
Open Access | Times Cited: 16
Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
Crystal M. Proud, Eugenio Mercuri, Richard S. Finkel, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 11, pp. 2155-2160
Open Access | Times Cited: 15
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
Katarzyna Kotulska, Aviva Fattal‐Valevski, Jana Haberlová
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 31
The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy
Mar Costa‐Roger, Laura Campello Blasco, Ivon Cuscó, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 9029-9029
Open Access | Times Cited: 29
Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec—Preliminary Results
Venla Soini, Gudrun Schreiber, Bernd Wilken, et al.
Children (2023) Vol. 10, Iss. 6, pp. 998-998
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top